Moderna, Inc.

MRNASEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1682852

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$6.8B	$19.3B	$18.5B	—	—
Cost of Goods and Services Sold	$4.7B	$5.4B	$2.6B	$8.0M	$0.00
Research and Development Expense	$4.8B	$3.3B	$2.0B	$1.4B	$496.0M
Operating Expenses	—	—	—	—	—
Operating Income (Loss)	-$4.2B	$9.4B	$13.3B	-$763.0M	-$546.0M
Other Nonoperating Income (Expense)	-$124.0M	-$45.0M	-$29.0M	-$6.0M	-$8.0M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$3.9B	$9.6B	$13.3B

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$14.1B	$18.4B	$25.9B	$24.7B	$7.3B
Assets, Current	$8.1B	$10.3B	$13.4B	$16.1B	$6.3B
Cash and Cash Equivalents, at Carrying Value	$2.9B	$3.2B	$6.8B	$2.6B	$236.0M
Accounts Receivable, after Allowance for Credit Loss, Current	$358.0M	$892.0M	$1.4B	$3.2B	$1.4B
Inventory, Net	$117.0M	$202.0M	$949.0M	$1.4B	$47.0M
Liabilities	$3.2B	$4.6B	$6.7B	$10.5B	$4.8B
Liabilities, Current	$2.2B	$3.0B	$4.9B	$9.1B

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$3.1B	$5.0B	$13.6B	$2.0B	-$459.0M
Net Cash Provided by (Used in) Investing Activities	$4.2B	-$5.2B	-$8.5B	-$1.7B	-$15.0M
Net Cash Provided by (Used in) Financing Activities	-$1.4B	-$3.4B	-$873.0M	$2.0B	$52.0M
Payments to Acquire Property, Plant, and Equipment	$707.0M	$400.0M	$284.0M	$68.0M	$32.0M
Payments for Repurchase of Common Stock	$1.2B	$3.3B	$857.0M	$0.00	$0.00

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)